Midas Pharma GmbH Sustainability Profile
Midas Pharma GmbH, a prominent player in the pharmaceutical industry, is headquartered in Germany and operates extensively across Europe and beyond. Founded in 1994, the company has established itself as a trusted partner in the development and distribution of innovative healthcare solutions. Midas Pharma focuses on contract development and manufacturing, offering a diverse range of services that include drug formulation, regulatory support, and supply chain management. Their commitment to quality and customer-centric approach sets them apart in a competitive market. With a strong emphasis on research and development, Midas Pharma has achieved significant milestones, positioning itself as a leader in the pharmaceutical sector. The company’s dedication to excellence is reflected in its robust portfolio of products and services, catering to the evolving needs of the healthcare landscape.
DitchCarbon Score
How does Midas Pharma GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Midas Pharma GmbH's score of 17 is lower than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Midas Pharma GmbH's reported carbon emissions
In 2024, Midas Pharma GmbH reported carbon emissions of approximately 230,000 kg CO2e from Scope 1 sources in Germany. This marks an increase from 2023, when emissions were about 201,000 kg CO2e. On a global scale, the company disclosed total emissions of approximately 249,000 kg CO2e for Scope 1, 16,000 kg CO2e for Scope 2, and a significant 679,714,000 kg CO2e for Scope 3 emissions, which include categories such as purchased goods and services (about 678,587,000 kg CO2e) and business travel (approximately 776,000 kg CO2e). Despite these figures, Midas Pharma GmbH has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks like the Science Based Targets initiative (SBTi). The company operates independently without cascading emissions data from a parent organization, ensuring that its reported figures reflect its own operational impact. Overall, while Midas Pharma GmbH has made strides in emissions reporting, the lack of defined climate commitments highlights an area for potential improvement in their sustainability strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 217,000 | 000,000 |
| Scope 2 | 16,000 | 00,000 |
| Scope 3 | - | 000,000,000 |
How Carbon Intensive is Midas Pharma GmbH's Industry?
How Carbon Intensive is Midas Pharma GmbH's Location?
Midas Pharma GmbH's Scope 3 Categories Breakdown
Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 100% of Scope 3 emissions.
Top Scope 3 Categories
Midas Pharma GmbH's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Midas Pharma GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
